Furthermore, PARP inhibitors are a class of therapeutic agents that primarily target and inhibit PARP1/2 proteins, thereby inducing “synthetic lethality” in tumor cells harboring BRCA1/2 mutations or exhibiting HRD [323]. Here, PARP1 is linked to neoplasm.